Glioblastoma
Glioblastoma is a fast-growing and aggressive type of brain cancer that arises from glial cells, often leading to severe symptoms and a challenging prognosis.
HER2-Positive Glioblastoma: NK-92/5.28.z Cells and Ezabenlimab
We are investigating a new treatment combining NK-92/5.28.z cells with Ezabenlimab for patients with recurrent HER2-positive glioblastoma. This study aims to see if this combination can improve treatment outcomes.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Goethe University Frankfurt
Dr. Senckenbeg Institute for Neurooncology
Frankfurt am Main, Germany
Universitaetsklinikum Heidelberg AöR
Department of Neurosurgery
Heidelberg, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
Neurochirurgische Klinik und Poliklinik
Mainz, Germany
Sponsor: Goethe University Frankfurt
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.